Cancer
Conditions
Interventions
investigational material(s)
Generic name etc : LY2584702
INN of investigational material :
Therapeutic category code : 429 Other antitumor agents
Dosage and Administration for Investigational materia
Sponsors
Eli Lilly Japan K.K.
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Have histological or cytological evidence of a diagnosis of advanced and/or metastatic cancer (solid tumors) that is refractory to standard therapy and/or therapies known to provide clinical benefit, or for which no standard therapy exists. Have the presence of disease amenable to efficacy assessment as defined by the Response Evaluation Criteria In Solid Tumors(RECIST). Japanese patients who have advanced non-measurable disease with elevation of a validated tumor marker may be eligible, if discussed and agreed upon by the investigator and Lilly. Have adequate organ function including. Have a performance status of less than or equal to 2 on the Eastern Cooperative Oncology Group scale. Have discontinued all previous therapies for cancer, including chemotherapy, radiotherapy, cancer-related hormonal therapy prior to study enrollment and recovered from the acute effects of therapy. Have an estimated life expectancy of 12 weeks or greater. Are able to swallow capsules.
Exclusion criteria
Exclusion criteria:
Outcome results
None listed